Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Anacor Pharmaceuticals Inc    

News SummaryMost relevantAll newsSector newsTweets 

Anacor Pharmaceuticals Inc : Investors Eye Catching Stocks: (NASDAQ: ANAC), (NYSE: RDN)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/09/2013 | 07:10am CEST

New York (April 9th, 2013) - Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis (TB).

Additionally, Anacor will create an expanded library of boron compounds to screen for additional potential drug candidates to treat neglected diseases and will provide access to the expanded library compounds for neglected disease research to the Gates Foundation, and others, including academic, governmental and other non-profit institutions or equivalent entities.

Under the agreement, Gates Foundation will pay Anacor $17.7 million as well as invest $5 million in Anacor common stock.

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Get the daily trend analysis reports on ANAC here:


Radian Group Inc. (NYSE: RDN) announced, last Thursday, that it has reached a settlement agreement with the Consumer Financial Protection Bureau (CFPB) to resolve a previously disclosed federal investigation of the company’s participation in captive reinsurance arrangements.

As part of this settlement, which was filed earlier today in the U.S. District Court for the Southern District of Florida, Radian agreed not to enter into new captive reinsurance arrangements for a period of ten years and to pay a civil penalty of $3.75 million.

“We are pleased to put this behind us,” stated Teresa Bryce Bazemore, president of Radian Guaranty. “While we believe our captive arrangements complied with RESPA and caused no harm to consumers, this settlement was an opportunity to eliminate distractions at an acceptable cost so that we can continue our primary focus of writing new, profitable mortgage insurance and helping low down-payment borrowers realize the dream of homeownership,” Ms. Bazemore said.

Find out where RDN could be headed in the very short term here:


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
[email protected]

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
2016 PFIZER : completes acquisition of Anacor Pharmaceuticals
2016 PFIZER : completes acquisition of Anacor
2016 ANACOR PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Asset..
2016DJJazz Pharmaceuticals Agrees to Buy Celator for About $1.5 Billion
2016DJJazz Pharmaceuticals Nears Deal to Buy Celator for About $1.5 Billion
2016 Anacor received rival bid before Pfizer deal - filing
2016 Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Ana..
2016 Levi & Korsinsky, LLP Announces Investigation Into Whether the Sale of Anacor..
2016 ANACOR SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation of ..
2016 Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Ana..
More news
Sector news : Biotechnology & Medical Research - NEC
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/24 We're Hesitant On AnaptysBio's IPO
01/18 MERGERS AND ACQUISITIONS IN 2016 : Pause For Breath In A Shifting Market
2016 New Oral Psoriasis Drug Tops Cellceutix Catalysts
2016 BIOTECH FORUM DAILY DIGEST : A Volatile Few Days, Some Small Caps Blow Up, Spotl..
2016 Novan's IPO - Buying A Dollar For Twenty Cents
Income Statement Evolution
More Financials
Paul L. Berns Chairman, President & Chief Executive Officer
Graeme Bell Chief Financial Officer & Executive Vice President
Jacob J. Plattner Senior Vice President-Research
Lee T. Zane Chief Medical Officer & Senior Vice President
Margaret M. Madden Secretary, Director & Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP26.33%15 596
CELLTRION, INC.--.--%12 276
More Results